Schering Corporation

Merck Sharp + Dohme Corp.

Pharmacopeia Inc.

Schering Coporation

James J-s Wang

Alan B Cooper

Jagdish A Desai

Viyyoor Moopil Girijavallabhan

Ronald J Doll

Hugh Y Zhu

Joseph Michael Kelly

Gerald Wayne Shipps, Jr

Yongqi Deng

Neng-Yang Shih

Timothy J Guzi

Dinanath F Rane

Xiaolei Gao

Carmen S Alvarez

Sobhana Babu Boga

Liang Zhu

Yang Nan

Abdul-Basit Alhassan

F George Njoroge

Arthur G Taveras

Anil K Saksena

Vincent Stewart Madison

M Arshad Siddiqui

Sunil Paliwal

Alan W Hruza

Li Xiao

Hon-Chung Tsui

Robert Sun

Jianping Chao

Ahmed Abdi Samatar

Tarik Lalwani

Cynthia J Aki

Tong Wang

Johan A Ferreira

Youhao Dong

John J Baldwin

Ge Li

Alan K Mallams

Adriano Afonso

Raymond G Lovey

Huw M Nash

Patrick A Pinto

Jay Weinstein

Kartik M Keertikar

Ray Anthony James

Chia-Yu Huang

Bancha Vibulbhan

Mehul F Patel

Patrick J Curran

Bama Santhanam

Keith P Minor

Azim Alan Celebi

Sie-Mun Lo

Xin Yao

D Allen Annis

Yiji Wu

Subrahmanyam Gudipati

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1). 

Compounds that are ERK inhibitors

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. 

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Disclosed are novel tricyclic compounds of the formula: and a pharmaceutically acceptable salts or solvates thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are uses of the compounds of formula (I) for the manufacture of a medicament for the treatment of cancer.

Farnesyl protein transferase inhibitors as antitumor agents

The present invention provides compounds of formula I wherein X, Y, R-Rare as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided. 

Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents

Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Farnesyl protein transferase inhibitors

Compounds useful for inhibition of farnesyl protein transferase

Novel tricyclic N-cyanoimine compounds and pharmaceutical compositions of formula (1.0) ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein a, b, c, d, R.sup.1 -R.sup.8, X and Z are defined herein. Such compounds are inhibitors of the enzyme, farnesyl protein transferase. The compounds are useful for inhibiting Ras function and therefore inhibiting the abnormal growth of cells, in a mammals such as a human.

Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein

Growing community of inventors

Westfield, NJ, United States of America

James J-s Wang